Pacira BioSciences, Inc.

NASDAQ:PCRX

Drug Manufacturers - Specialty & Generic

Healthcare
$36.48 -0.79%

-$0.18 today

Market cap
$1.46B
Beta
0.29
P/E (TTM)
176.9
EPS (TTM)
$0.13
52W Low $18.80High $27.64

Volume 1.81M

Average 0.57M

PCRX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Pacira BioSciences, Inc.NASDAQ: PCRX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$1.57M, compared with $8.56M a year earlier. Trailing-twelve-month accounts receivables was -$20.87M. Over 3 fiscal years it compounded at +72.9% a year.

Context

  • Accounts receivables amounted to 1.5% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Accounts receivables grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$1.57M or moves back toward the trailing-twelve-month quarterly average of -$5.22M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.57M-82.2% QoQ
Last fiscal yearDec 2025
-$10.74M+38.6% YoY
LTMMar 2026
-$20.87M+571.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-118.3%——
1 year+38.6%——
3-year CAGR+72.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(10.74M) USD
Year-over-year change
-38.6%

Accounts Receivables vs competitors

How PCRX compares with its peers on the latest reported figures

  • PCRX's LTM Mar 2026 accounts receivables of $20.87M is the 2nd largest of the 4 companies compared; the peer median is $60K.
  • Its year-over-year change of +571.9% is the highest of 4, against a peer median of -99.4%.
  • Accounts receivables amounts to 2.8% of revenue for PCRX, versus a peer median of 5.7%.
PCRX Competitors Peer median
Accounts Receivables for PCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$47.41M -506.5%+10.9%5.7%
PCRXPacira BioSciences, Inc.LTM Mar 2026$20.87M +571.9%+72.9%2.8%
SCLXScilex Holding CompanyLTM Mar 2026$2.42M -48.1%—7.2%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$60K -99.4%—0.0%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding PCRX) $60K-99.4%+10.9%5.7%

Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income41.98M15.91M41.96M(99.56M)7.03M
Depreciation & Amortization28.55M91.5M75.57M78.79M91.02M
Deferred Income Tax10.87M(7.95M)15.62M20.62M6.48M
Stock-Based Compensation42.25M48.09M47.9M51.17M57.5M
Change in Working Capital(18.67M)(16.43M)(45.78M)(18.52M)(38.27M)
Accounts Receivables(10.43M)(2.08M)(7.16M)(7.75M)(10.74M)
Inventory(4.47M)2.49M(8.29M)(20.93M)(27.57M)
Accounts Payables(10.26M)6.27M916K3.08M(5.6M)
Other Working Capital6.49M(23.11M)(31.24M)7.07M5.64M
Other Non-Cash Items20.75M14.15M19.39M156.89M28.22M
Operating Cash Flow125.72M145.27M154.65M189.39M151.99M
Capital Expenditures(45.87M)(30.08M)(15.16M)(10.64M)(15.33M)
Acquisitions (Net)(420.04M)000(16.7M)
Purchases of Investments(628.68M)(400.69M)(144.37M)(252.21M)(142.29M)
Sales of Investments1.08B237.58M237.07M179.57M268.88M
Other Investing Activities(4M)(32M)004.93M
Investing Cash Flow(20.79M)(225.19M)77.54M(83.28M)99.48M
Debt Repayment363.75M(427.69M)(180.76M)76.62M(218.99M)
Common Stock Issued26.66M27.34M003.3M
Common Stock Repurchased00(106K)(25M)(148.33M)
Dividends Paid00000
Other Financing Activities(9.71M)(1.18M)(2.16M)(34.25M)(5.62M)
Financing Cash Flow380.69M(401.53M)(183.03M)17.36M(369.63M)
Effect of Forex Changes0000(77K)
Net Change in Cash485.62M(481.44M)49.16M123.48M(118.23M)
Free Cash Flow79.85M115.2M139.49M178.75M136.66M

Pacira BioSciences, Inc.

NASDAQ:PCRX

Intrinsic Alpha fair value

Locked

Current Price

$36.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.